QualityStocks would like to highlight Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. Its principal product is the Intermezzo, a low dose sublingual formulation of zolpidem as a sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep.
In the company’s news yesterday,
Transcept Pharmaceuticals announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating TO-2061 which is added as an adjunctive therapy for patients with obsessive-compulsive order (OCD). These patients have not responded adequately to standard first-line treatment with a currently approved OCD medication. These medications include the selective serotonin re-uptake inhibitors (SSRIs) and the tricyclic agent, clomipramine. There is no current FDA-approved adjunctive therapy for these treatment-resistant patients.
TO-2061 is a low dose formulation of ondansetron, a serotonin subtype 3 (5-HT3) receptor antagonist, which has been approved for the treatment of nausea and vomiting caused by chemotherapy and radiation therapy, and for the prevention of post-surgical nausea and vomiting. Ondansetron has an established history of clinical use as a safe and effective treatment at a typical daily dose of 16-24 milligrams.
TO-2061 is being studied at total daily doses of 1-1.5 milligrams, where two pilot studies have already been done. The Phase 2 study is a double-blind, placebo-controlled trial to evaluate the safety and efficacy of TO-2061 as an adjunct in 168 OCD patients who have not responded to conventional therapy. Transcept plans to announce top-line results of this study sometime in the first quarter of 2013.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
